^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Neuroendocrine Tumor
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/21/2022
    Excerpt:
    Neuroendocrine and Adrenal Tumors...Locoregional unresectable/metastatic disease: Systemic therapy...Dabrafenib + trametinib (if BRAF V600E mutation-positive)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    BMJ Case Rep
    Title:

    BRAF V600E-mutated combined large cell neuroendocrine carcinoma and adenocarcinoma responding to targeted therapy

    Published date:
    12/20/2021
    Excerpt:
    We present a case of combined large cell neuroendocrine carcinoma (LCNEC), harbouring a BRAF V600E mutation, which significantly benefited from BRAF-targeted therapy…. Next-generation sequencing revealed a BRAF V600E mutation, and a combination therapy with dabrafenib and trametinib was initiated. The patient had a good response to treatment.
    DOI:
    http://dx.doi.org/10.1136/bcr-2021-243295
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Discov
    Title:

    BRAFV600E Mutations in High Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy

    Excerpt:
    A 70-year-old female presented with rectal bleeding from a fungating rectal mass, which on biopsy revealed a poorly differentiated high-grade (grade 3) rectal neuroendocrine tumor with a Ki67 proliferation index greater than 60%...Genomic analysis revealed a BRAFV600E...she was transitioned to dabrafenib 150mg twice daily and trametinib 2mg once daily and her symptoms resolved within 10 days of treatment...She obtained a dramatic radiographic response within five weeks that continues for over seven months at the time of submission...
    DOI:
    10.1158/2159-8290.CD-15-1192